Ledismase
Highest phase reached
Phase 2
Drug type
Enzyme
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Enzyme
- Drug name
- Ledismase
- dismutase superoxide human copper zinc subunit cyclic 57 146 disulfide dim
- DISMUTASE, SUPEROXIDE (HUMAN COPPER-ZINC SUBUNIT), CYCLIC (57->146)-DISULFIDE, DIM
- edismase
- Edismase
- EDISMASE (GENETICAL RECOMBINATION)
- EDISMASE [JAN]
- edismase genetical recombination
- edismase jan
- human sod 1
- Human sod-1
- ledismasa
- Ledismasa
- ledismase
- Ledismase
- ledismase [INN]
- ledismase inn
- oxsodrol
- Oxsodrol
- recombinant superoxide dismutase human
- RECOMBINANT SUPEROXIDE DISMUTASE, HUMAN
- SUPEROXIDE DISMUTASE (CU-ZN) HUMAN
- Superoxide dismutase (human)
- superoxide dismutase cu zn human
- superoxide dismutase human
- SUPEROXIDE DISMUTASE HUMAN (E. COLI)
And 5 more, listed on the interactive page.
- CAS registry numbers
- 149394-67-2
- ChEMBL ID
- CHEMBL2109126
- PubChem compound IDs
- 72941695
- RxNorm IDs (RxCUI)
- 1742510
- FDA ingredient codes (UNII)
- 0786H5RV0T
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Drug name stem
- -ase
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (39)
- A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
- A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas
- A Study to Learn About a Vaccine Against E Coli in Healthy Adults
- Additive Effect of Probiotics (Mutaflor®) in Patients With Ulcerative Colitis on 5-ASA Treatment.
- Anti-inflammatory Effects of GTS-21 After LPS
- Assessing NOS Uptake With PET Imaging in Lung Inflammation
- Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli
- Clinical Experiment of Helicobacter Pylori Transmission
- E. Coli 83972 Induced Asymptomatic Bacteriuria (ABU) in Patients With Recurrent Urinary Tract Infections (UTI)
- E. Coli Nissle in Oncology
- Effects of BCG on Immune Response
- Enteroaggregative E.Coli (EAEC)
- Evaluation of Phage Therapy for the Treatment of Escherichia Coli and Pseudomonas Aeruginosa Wound Infections in Burned Patients
- Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
- Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults
- Individual Differences in Acute Response to Experimental Inflammation: Microcirculatory Changes and Psychological Predictors
- Inflammatory Challenge in Human Aggression.
- Investigation of the Effect of E.-Coli-Nissle as Supporting Therapy to Standard Care of Diabetes Mellitus Type II
- Low-dose Challenge Model With Enterotoxigenic E Coli
- Low-Dose Endotoxemia and the Acute Phase Response